Genentech has called a truce with Taiwanese biosimilar firm JHL Biotech, which allegedly stole trade secrets to help it develop copycats to top-selling cancer drugs. The Roche unit said the settlement ...

Convicted of misusing trade secrets to copy blockbuster Genentech drugs Pleaded guilty to trade-secret, wire-fraud conspiracy under agreement JHL and Genentech settled civil case last year (Reuters) - ...

JHL Biotech announced today that China’s FDA has accepted its application for the use of JHL1101 in Phase 1 and Phase 3 clinical trials in non-Hodgkin’s lymphoma patients. JHL1101 is a rituximab ...

JHL founders were former Genentech employees Trade secrets allegedly used to speed biosimilar production Founders allegedly defrauded Sanofi out of $101 million (Reuters) - The U.S. Department of ...

Deal will cover Rituximab biosimilar and other JHL pipeline products. Sanofi is investing $80 million in biopharma JHL Biotech as part of a strategic collaboration to develop biologics for the Chinese ...